R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15
J Comp Eff Res. 2024 Mar 28:e240033. doi: 10.57264/cer-2024-0033. Online ahead of print.ABSTRACTIn this latest update we discuss real-world evidence (RWE) guidance from the leading oncology professional societies, the American Society of Clinical Oncology and the European Society for Medical Oncology, and the PRINCIPLED practical guide on the design and analysis of causal RWE studies.PMID:38546012 | DOI:10.57264/cer-2024-0033 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - March 28, 2024 Category: General Medicine Authors: Alejandra Castanon Benjamin D Bray Sreeram V Ramagopalan Source Type: research

Digital variance angiography in patients undergoing lower limb arterial recanalization: cost-effectiveness analysis within the English healthcare setting
Conclusion: The use of DVA could result in a decrease in costs and an increase in QALYs over a lifetime, compared with existing imaging practice. The potential for this technology to offer an economically viable alternative to existing image processing methods, through a reduction in contrast media volume and radiation exposure, has been demonstrated.PMID:38517149 | DOI:10.57264/cer-2023-0068 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - March 22, 2024 Category: General Medicine Authors: Amir Ansaripour Eoin Moloney Michael Branagan-Harris Lorenzo Patrone Mehdi Javanbakht Source Type: research

Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods
Conclusion: In ITC analyses, oliceridine significantly reduced the incidence of nausea and/or vomiting or the need for antiemetics in orthopedic surgery compared with hydromorphone and a non-significant trend toward reduced risk versus fentanyl.PMID:38497192 | DOI:10.57264/cer-2023-0041 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - March 18, 2024 Category: General Medicine Authors: Joseph Biskupiak Gary Oderda Diana Brixner Todd L Wandstrat Source Type: research

Understanding economic analysis and cost-effectiveness of CT scan-guided, 3-dimensional, robotic-arm assisted lower extremity arthroplasty: a systematic review
Conclusion: Robotic-arm assisted joint arthroplasty patients had shorter lengths of stay and cost savings based on their 90-day episodes of care, among other metrics. Payors would likely benefit from encouraging the use of this CT-based robotic technology.PMID:38488048 | DOI:10.57264/cer-2023-0040 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - March 15, 2024 Category: General Medicine Authors: Kara Sarrel Daniel Hameed Jeremy Dubin Michael A Mont David J Jacofsky Andr éa B Coppolecchia Source Type: research

Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study
Conclusion: Treating patients hospitalized for COVID-19 with remdesivir is associated with a statistically significant reduction in 30-day COVID-19-related and all-cause readmission across variant time periods. These findings indicate that the clinical benefit of remdesivir may extend beyond the COVID-19 hospitalization.PMID:38420658 | DOI:10.57264/cer-2023-0131 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - February 29, 2024 Category: General Medicine Authors: Essy Mozaffari Aastha Chandak Robert L Gottlieb Chidinma Chima-Melton Andre C Kalil Vishnudas Sarda Celine Der-Torossian Thomas Oppelt Mark Berry Alpesh N Amin Source Type: research